Staccato Loxapine PK in Smokers and Nonsmokers
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The objective of this trial was to assess the pharmacokinetics of a single dose of 10 mg Staccato Loxapine administered to smokers compared to nonsmokers.
Full description
Pharmacokinetics and sedation pharmacodynamics were studied using a visual analog scale were studied in male and female adult subjects (nonsmokers and smokers) following a single dose of 10 mg of inhaled loxapine. Blood samples were drawn at predose, 30 seconds, 1, 2, 3, 10, 30, and 60 minutes, and 2, 6, 12, and 24 hours after dosing. Loxapine and 8-OH-loxapine were analyzed using reverse-phase liquid chromatography coupled with a tandem mass spectrometer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Normal spirometry at screening and in good general health as determined by a complete medical history, physical examination, 12-lead ECG, blood chemistry profile, hematology, and urinalysis,
- Smokers must have a history of smoking > 15 cigarettes/day currently and for at least the last 2 years,
- Nonsmokers must have never smoked > 5 cigarettes/day and not smoking at all for at least the last 2 years.
Exclusion criteria
- Any acute illness in the 5 days,
- Use of a bronchodilator for the treatment of wheezing within 12 months, OR
- Any other disease or condition, by history, physical examination, or laboratory abnormalities that would present undue risk to the subject, or may confound the interpretation of study results.
Trial design
Primary purpose
Allocation
Interventional model
Masking
35 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal